Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tibotec's Intelence approved in Europe

This article was originally published in Scrip

Executive Summary

Tibotec's Intelence (etravirine) has been approved by the European Commission for the treatment of HIV-1 in antiretroviral treatment-experienced adults. Tibotec said that Intelence will be available across the EU, but said that the timing of its launch would be dependent on pricing and reimbursement negotiations in individual countries. Intelence, a non-nucleoside reverse transcriptase inhibitor, was approved in the US in January and received a positive opinion from the EU's CHMP in June (Scrip Online, June 27th, 2008).

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC003438

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel